Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Can a ‘second-look’ ctDNA test rescue patients who initially appeared low-risk after CRC surgery?
The GALAXY study suggests yes.
Patients with resected stage I-IV CRC who were:
- ctDNA-negative at 4 weeks
- but converted to ctDNA-positive at 12 weeks
derived a major benefit from delayed adjuvant chemotherapy (ACT).
Key findings:
- N=1,034 initially ctDNA-negative patients
- 36 became ctDNA-positive at 12 weeks
- ACT significantly improved DFS vs observation:
- HR 0.30 (p=0.0165)
- 2-year DFS: 45.5% vs 9.8%
Meanwhile, patients remaining ctDNA-negative at both timepoints had excellent outcomes regardless of ACT:
- 2-year DFS: 87.1% vs 84.1%
Takeaway: A single postoperative ctDNA test may not be enough.
Dynamic ctDNA monitoring at BOTH 4 and 12 weeks could redefine who truly needs adjuvant chemotherapy after CRC surgery. This is where precision oncology gets real.”
Title: Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients
based on ctDNA dynamics across two timepoints: Results from
GALAXY study.
Authors: Mitsuru Yokota, Hideaki Bando, Yoshiaki Nakamura, Daisuke Kotani, Saori Mishima, Koji Ando, Stephanie A. Sanchez, Kim Magee, Charuta C. Palsuledesai, Robert W. Lentz, Adham A. Jurdi, Alexey Aleshin, Hiroya Taniguchi, Jun Watanabe, Takeshi Kato, Yusuke Suwa, Keiji Hirata, Naoya Akazawa, Takayuki Yoshino, Eiji Oki
Read the Full Abstract.
Other articles featuring Rishabh Jain on OncoDaily.
